Aromatase inhibitors (AIs) are becoming the hormonal ... or anastrozole versus the previous standard of 5 years of adjuvant tamoxifen and support using an AI (exemestane, anastrozole or letrozole ...

A number of adjuvant breast cancer trials are currently evaluating all 3 third-generation aromatase inhibitors relative to the current standard, tamoxifen for 5 years. In comparing efficacy and ...

Aromatase inhibitors are a group of endocrine agents that lower the ... monthly in women with hormone receptor positive breast cancer that has recurred. Tamoxifen belongs to a group of drugs known as ...